January 15th 2024
The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.
Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.
January 11th 2024
The China National Medical Products Administration has accepted the NDA seeking approval of sovleplenib in patients with primary immune thrombocytopenia.
Charles Swanton, FRCP, BSc, PhD, has a craving to understand cancer’s evolution, and his list of achievements can prove it.
January 10th 2024
The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.
January 9th 2024
The NCCN has updated its guidelines for soft tissue sarcoma to include nirogacestat as a systemic therapy option for patients with desmoid tumors.
Expert oncologists who treat patients with advanced renal cell carcinoma discuss updates from clinical trials presented during the 2023 ESMO Congress.
January 8th 2024
Although the severity of the shortage of chemotherapy agents, particularly with the platinum-based therapies cisplatin and carboplatin, has receded from the heights seen earlier in 2023, clinicians are still dealing with its ramifications and having to strategically manage how they employ certain chemotherapies.
December 29th 2023
Charles S. Kamen, PhD, MPH, discusses key developments and efforts that are planned and underway to further the progress that has been observed in terms of increasing cancer equity in sexual and gender minority individuals.
December 26th 2023
The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.
December 24th 2023
In a full-circle scenario, Cedars-Sinai Cancer, based in Los Angeles, California, welcomed back Margaret Liang, MD, MSHPM, in July 2023 to the institution where she completed her fellowship.
December 22nd 2023
The FDA has accepted and granted priority review to the biologics license application seeking the approval of the HER3-directed antibody-drug conjugate patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.
The implementation and subsequent optimization of a health information technology module within the electronic health record has allowed clinicians across a diverse health care system to identify barriers to improve discrete capture of cancer staging and design solutions to address them.
December 21st 2023
The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.
December 20th 2023
Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.
Tucatinib, which inhibits phosphorylation of HER2/3 resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, has shown promise for patients with brain metastases as the small molecule inhibitor of HER2 can cross the blood-brain barrier.
December 15th 2023
Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
December 13th 2023
The presence of mutated SRSF2 in knock-in mouse models of JAK2 V617F–driven myeloproliferative neoplasms reduced the rate of polycythemia and hampered hematopoietic progenitor functions.
December 12th 2023
Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.